KPRX Profile
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, is dedicated to developing and commercializing innovative therapies for the treatment of ophthalmic diseases in the United States. The company's lead product, KIO-301, is a groundbreaking small molecule in Phase 1 clinical trials designed to act as a photoswitch, potentially restoring vision in patients with inherited and age-related degenerative retinal diseases. This cutting-edge therapy aims to address significant unmet medical needs in ophthalmology, offering hope to individuals suffering from severe vision impairments.
In addition to KIO-301, Kiora Pharmaceuticals is advancing KIO-101, an eye drop currently in Phase 2 clinical trials. KIO-101 is being developed for the treatment of the ocular presentation of rheumatoid arthritis and non-infectious posterior uveitis. This therapy represents a novel approach to managing inflammatory eye conditions associated with systemic diseases, providing targeted relief and improving patients' quality of life. The company's focus on developing such targeted therapies underscores its commitment to addressing complex ocular disorders.
Kiora Pharmaceuticals is also progressing KIO-201, an eye drop in Phase 3 clinical trials, aimed at treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. KIO-201 is designed to enhance the healing process and reduce post-operative complications, thereby improving surgical outcomes and patient satisfaction. This product exemplifies the company's strategy of developing therapies that enhance existing ophthalmic procedures and address critical gaps in treatment options.
Founded in 1998 and headquartered in Encinitas, California, Kiora Pharmaceuticals was formerly known as Eyegate Pharmaceuticals, Inc. before changing its name in November 2021. The company leverages its extensive expertise in ophthalmology to develop a robust pipeline of therapeutic candidates, positioning itself at the forefront of innovation in eye care. By focusing on novel treatments for a range of ophthalmic diseases, Kiora Pharmaceuticals aims to transform the lives of patients with vision-threatening conditions and establish itself as a leader in the field of ocular therapeutics.
|
